Nivolumab (NIVO) plus chemotherapy (chemo) vs chemo in patients (pts) with EGFR-mutated metastatic non-small cell lung cancer (mNSCLC) with disease progression after EGFR tyrosine kinase inhibitors (TKIs) in CheckMate 722

T. S. K. Mok; K. Nakagawa; K. Park; Y. Ohe; N. Girard; H. R. Kim; Yi Wu; J. Gainor; S-H. Lee; Chao-Hua. Chiu; K. Sang-We; Y. Cheng-Ta; W. Liang; L. Wu; Miffy Chia-Yu Lin; J. Samol; X. Zhang; J. Sylvester; S. Li; Cheng-Ta Yang

doi:10.1016/j.annonc.2022.10.350

Nivolumab (NIVO) plus chemotherapy (chemo) vs chemo in patients (pts) with EGFR-mutated metastatic non-small cell lung cancer (mNSCLC) with disease progression after EGFR tyrosine kinase inhibitors (TKIs) in CheckMate 722

T. S. K. Mok
, K. Nakagawa
, K. Park
, Y. Ohe
, N. Girard
, H. R. Kim
, Yi Wu
, J. Gainor
, S-H. Lee
, Chao-Hua. Chiu
, K. Sang-We
, Y. Cheng-Ta
, W. Liang
, L. Wu
, Miffy Chia-Yu Lin
, J. Samol
, X. Zhang
, J. Sylvester
, S. Li
, Cheng-Ta Yang

Department of Respiratory Therapy

Research output: Contribution to journal › Journal Article › peer-review

Original language	American English
Journal	Annals of Oncology
Volume	38
Issue number	9
DOIs	https://doi.org/10.1016/j.annonc.2022.10.350
State	Published - 2022

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1016/j.annonc.2022.10.350

Cite this

Mok, T. S. K., Nakagawa, K., Park, K., Ohe, Y., Girard, N., Kim, H. R., Wu, Y., Gainor, J., Lee, S.-H., Chiu, C.-H., Sang-We, K., Cheng-Ta, Y., Liang, W., Wu, L., Lin, M. C.-Y., Samol, J., Zhang, X., Sylvester, J., Li, S., & Yang, C.-T. (2022). Nivolumab (NIVO) plus chemotherapy (chemo) vs chemo in patients (pts) with EGFR-mutated metastatic non-small cell lung cancer (mNSCLC) with disease progression after EGFR tyrosine kinase inhibitors (TKIs) in CheckMate 722. Annals of Oncology, 38(9). https://doi.org/10.1016/j.annonc.2022.10.350

@article{808ab8c8c1ef428a85d9002e2e481c04,

title = "Nivolumab (NIVO) plus chemotherapy (chemo) vs chemo in patients (pts) with EGFR-mutated metastatic non-small cell lung cancer (mNSCLC) with disease progression after EGFR tyrosine kinase inhibitors (TKIs) in CheckMate 722",

author = "Mok, \{T. S. K.\} and K. Nakagawa and K. Park and Y. Ohe and N. Girard and Kim, \{H. R.\} and Yi Wu and J. Gainor and S-H. Lee and Chao-Hua. Chiu and K. Sang-We and Y. Cheng-Ta and W. Liang and L. Wu and Lin, \{Miffy Chia-Yu\} and J. Samol and X. Zhang and J. Sylvester and S. Li and Cheng-Ta Yang",

year = "2022",

doi = "10.1016/j.annonc.2022.10.350",

language = "American English",

volume = "38",

journal = "Annals of Oncology",

issn = "0923-7534",

publisher = "Elsevier Ltd",

number = "9",

}

Mok, TSK, Nakagawa, K, Park, K, Ohe, Y, Girard, N, Kim, HR, Wu, Y, Gainor, J, Lee, S-H, Chiu, C-H, Sang-We, K, Cheng-Ta, Y, Liang, W, Wu, L, Lin, MC-Y, Samol, J, Zhang, X, Sylvester, J, Li, S & Yang, C-T 2022, 'Nivolumab (NIVO) plus chemotherapy (chemo) vs chemo in patients (pts) with EGFR-mutated metastatic non-small cell lung cancer (mNSCLC) with disease progression after EGFR tyrosine kinase inhibitors (TKIs) in CheckMate 722', Annals of Oncology, vol. 38, no. 9. https://doi.org/10.1016/j.annonc.2022.10.350

Nivolumab (NIVO) plus chemotherapy (chemo) vs chemo in patients (pts) with EGFR-mutated metastatic non-small cell lung cancer (mNSCLC) with disease progression after EGFR tyrosine kinase inhibitors (TKIs) in CheckMate 722. / Mok, T. S. K.; Nakagawa, K.; Park, K. et al.
In: Annals of Oncology, Vol. 38, No. 9, 2022.

Research output: Contribution to journal › Journal Article › peer-review

TY - JOUR

T1 - Nivolumab (NIVO) plus chemotherapy (chemo) vs chemo in patients (pts) with EGFR-mutated metastatic non-small cell lung cancer (mNSCLC) with disease progression after EGFR tyrosine kinase inhibitors (TKIs) in CheckMate 722

AU - Mok, T. S. K.

AU - Nakagawa, K.

AU - Park, K.

AU - Ohe, Y.

AU - Girard, N.

AU - Kim, H. R.

AU - Wu, Yi

AU - Gainor, J.

AU - Lee, S-H.

AU - Chiu, Chao-Hua.

AU - Sang-We, K.

AU - Cheng-Ta, Y.

AU - Liang, W.

AU - Wu, L.

AU - Lin, Miffy Chia-Yu

AU - Samol, J.

AU - Zhang, X.

AU - Sylvester, J.

AU - Li, S.

AU - Yang, Cheng-Ta

PY - 2022

Y1 - 2022

U2 - 10.1016/j.annonc.2022.10.350

DO - 10.1016/j.annonc.2022.10.350

M3 - Journal Article

SN - 0923-7534

VL - 38

JO - Annals of Oncology

JF - Annals of Oncology

IS - 9

ER -